The simplified reference tissue model with 18F-Fallypride positron emission tomography: Choice of reference region

Molecular Imaging

Volumn 12, Issue 8, 2013, Pages

  Ishibashi, Kenji ^a   Robertson, Chelsea L ^a   Mandelkern, Mark A ^b   Morgan, Andrew T ^c   London, Edythe D ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING POTENTIAL; GROUP DIFFERENCES; KINETIC PROPERTIES; POSITRON EMISSION TOMOGRAPHY (PET); RECEPTOR LIGANDS; REFERENCE TISSUE MODEL; SAMPLE VARIANCE; VISUAL CORTEXES;

AMINES; BINDING ENERGY; KINETICS; NEUROPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TISSUE;

BRAIN;

BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; FALLYPRIDE; FLUORINE; METHAMPHETAMINE;

ADULT; ARTICLE; CEREBELLUM; DRUG ABUSE; HUMAN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; VISUAL CORTEX;

ADULT; AMPHETAMINE-RELATED DISORDERS; BENZAMIDES; CEREBELLUM; FLUORINE RADIOISOTOPES; HUMANS; METHAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; VISUAL CORTEX;

EID: 84893374132     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2013.00065     Document Type: Article

References (37)

1. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13:15-23, doi:10.1038/ jcbfm.1993.5.
2. Hume SP, Myers R, Bloomfield PM, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992;12:47-54, doi:10.1002/ syn.890120106.
3. Lammertsma AA, Bench CJ, Hume SP, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J CerebBlood Flow Metab 1996;16:42-52, doi:10.1097/00004647-199601000- 00005.
4. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4(3 Pt 1):153-8, doi:10. 1006/nimg.1996.0066
5. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 2000;41: 2083-8.
6. Osman S, Lundkvist C, Pike VW, et al. Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl- 11C]WAY-100635-explanation of high signal contrast in PET and an aid to biomathematical modelling. Nucl Med Biol 1998;25: 215-23, doi:10.1016/S0969-8051(97)00206-0.
7. Mukherjee J, Yang ZY, Das MK, Brown T. Fluorinated benzamide neuroleptics - III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)- methyl]-5-(3-[18F] fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 1995;22: 283-96, doi:10.1016/0969-8051(94)00117-3
8. Christian BT, Narayanan T, Shi B, et al. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab 2004;24: 309-22, doi:10.1097/01.WCB. 0000105020.93708.DD
9. Oikonen V, Allonen T, Nagren K, et al. Quantification of [carbonyl-(11)C]WAY-100635 binding: considerations on the cerebellum. Nucl Med Biol 2000;27:483-6, doi:10.1016/S0969- 8051(00)00116-5.
10. Slifstein M, Hwang DR, Huang Y, et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 2004;175:274- 86, doi:10.1007/s00213-004- 1830-x
11. Asselin MC, Montgomery AJ, Grasby PM, Hume SP. Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region. J Cereb Blood Flow Metab 2007;27:378-92, doi:10.1038/sj.jcbfm.9600340.
12. Narendran R, Mason NS, Chen CM, et al. Evaluation of dopamine D(2)/(3) specific binding in the cerebellum for the positron emission tomography radiotracer [(1)(1)C]FLB 457: implications for measuring cortical dopamine release. Synapse 2011;65:991-7, doi:10.1002/syn.20926
13. Vandehey NT, Moirano JM, Converse AK, et al. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11CFLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. J Cereb Blood Flow Metab 2010;30: 994-1007, doi:10.1038/jcbfm.2009.270.
14. Vernaleken I, Peters L, Raptis M, et al. The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab 2011;31:1958-66, doi:10.1038/jcbfm. 2011.73.
15. Son YD, Kim HK, Kim ST, et al. Analysis of biased PET images caused by inaccurate attenuation coefficients. J Nucl Med 2010;51: 753-60, doi:10.2967/jnumed.109.070326
16. Belanger MJ, Mann JJ, Parsey RV. OS-EM and FBP reconstructions at low count rates: effect on 3D PET studies of [11C] WAY- 100635. Neuroimage 2004;21:244-50, doi:10.1016/j.neuroimage. 2003.08.035.
17. Reilhac A, Tomei S, Buvat I, et al. Simulation-based evaluation of OSEM iterative reconstruction methods in dynamic brain PET studies. Neuroimage 2008;39:359-68, doi:10.1016/j.neuroimage. 2007.07.038.
18. Hall H, Farde L, Halldin C, et al. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996;23:115-23, doi:10.1002/(SICI)1098- 2396(199606)23:2,115::AID-SYN7. 3.0.CO;2-C
19. Lee B, London ED, Poldrack RA, et al. Striatal dopamine D2/D3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009;29:14734-40, doi: 10.1523/JNEUROSCI.3765-09.2009
20. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a wholebody PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997;38:1614-23
21. Brown AK, Mandelkern MA, Farahi J, et al. Sex differences in striatal dopamine D2/D3 receptor availability in smokers and nonsmokers. Int J Neuropsychopharmacol 2012;15:989-94.
22. Ishibashi K, Berman SM, Paz-Filho G, et al. Dopamine D2/D3 receptor availability in genetically leptin-deficient patients after long-term leptin replacement. Mol Psychiatry 2012;17:352-3, doi: 10.1038/mp.2011.156
23. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci 2000;47:1587-94, doi:10.1109/23. 873020.
24. Ardekani BA, Braun M, Hutton BF, et al. A fully automatic multimodality image registration algorithm. J Comput Assist Tomogr 1995;19:615-23, doi:10.1097/00004728-199507000-00022.
25. Volkow ND, Chang L, Wang GJ, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001; 158:2015-21, doi:10.1176/appi.ajp. 158.12.2015
26. Olsson H, Halldin C, Swahn CG, Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999;19:1164-73, doi:10.1097/00004647-199910000-00013.
27. Ito H, Sudo Y, Suhara T, et al. Error analysis for quantification of [(11)C]FLB 457 binding to extrastriatal D(2) dopamine receptors in the human brain. Neuroimage 2001;13:531-9, doi:10.1006/ nimg.2000.0717.
28. Ginovart N, Willeit M, Rusjan P, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-71
29. Vernaleken I, Klomp M, Moeller O, et al. Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3- receptor availability. Int J Neuropsychopharmacol 2013;16:745-54.
30. Kegeles LS, Slifstein M, Xu X, et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 2010;68:634-41, doi:10.1016/j.biopsych. 2010.05.027.
31. Landvogt C, Buchholz HG, Bernedo V, et al. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy. Epilepsia 2010;51:1699-706, doi:10.1111/j. 1528-1167.2010.02569.x.
32. Cropley VL, Innis RB, Nathan PJ, et al. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 2008;62:399-408, doi:10.1002/ syn.20506.
33. Siessmeier T, Zhou Y, Buchholz HG, et al. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med 2005;46:964-72
34. Riccardi P, Baldwin R, Salomon R, et al. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride. Biol Psychiatry 2008;63:241-4, doi:10.1016/j.biopsych. 2007.03.022.
35. Rominger A, Cumming P, Xiong G, et al. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics. Addict Biol 2011;17: 490-503, doi:10.1111/j.1369-1600. 2011.00355.x.
36. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-40, doi:10.1097/00004647- 199609000-00008.
37. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002;46: 170-88, doi:10.1002/syn.10128